후기 선 전이성 거세 방지 전립선 암 (MCRPC)에서 Pasritamig 대 위약에 대한 연구 (KLK2-comPAS)
Pasritamig (JNJ-78278343)의 3 상 무작위, 이중 맹검, 위약 대조 연구, 인간 Kallikrein 2, + 최상의지지 치료 대 전이성 거세 내성 전립선 암에 대한 최상의지지 치료에 대한 T 세포 리디렉션 제.
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Delft, 네덜란드, 2625 AD
- 모병
- Reinier de Graaf Gasthuis
-
Groningen, 네덜란드, 9728NT
- 완전한
- Martini Ziekenhuis
-
Hilversum, 네덜란드, 1212 VG
- 모병
- Tergooi
-
Hoofddorp, 네덜란드, 2134 TM
- 모병
- Spaarne Gasthuis
-
Maastricht, 네덜란드, 6229 HX
- 모병
- Maastricht UMC
-
Nijmegen, 네덜란드, 6532 SZ
- 모병
- Canisius-Wilhelmina ZH
-
Rotterdam, 네덜란드, 3015 GD
- 모병
- Erasmus MC
-
Zwolle, 네덜란드, 8025 AB
- 모병
- Isala Kliniek
-
-
-
-
-
Kaohsiung City, 대만, 833
- 모병
- Chang Gung Memorial Hospital
-
Taichung, 대만, 40705
- 모병
- Taichung Veterans General Hospital
-
Taichung, 대만, 435
- 모병
- Tungs' Taichung MetroHarbor Hospital
-
Taipei, 대만, 100
- 모병
- National Taiwan University Hospital
-
Taipei, 대만, 112
- 모병
- Taipei Veterans General Hospital
-
Taoyuan, 대만, 333
- 모병
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Daejeon, 대한민국, 35015
- 모병
- Chungnam National University Hospital
-
Goyang-si, 대한민국, 10408
- 모병
- National Cancer Center
-
Hwasungun, 대한민국, 58128
- 모병
- Chonnam National University Hwasun Hospital
-
Seoul, 대한민국, 05505
- 모병
- Asan Medical Center
-
Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center
-
Seoul, 대한민국, 03722
- 모병
- Severance Hospital Yonsei University Health System
-
Seoul, 대한민국, 06591
- 모병
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Braunschweig, 독일, 38126 DE
- 모병
- Staedtisches Klinikum Braunschweig
-
Duisburg, 독일, 47169
- 모병
- Urologicum Duisburg
-
Düsseldorf, 독일, 40225
- 모병
- Universitaetsklinikum Duesseldorf
-
Essen, 독일, 45147
- 모병
- Universitaetsklinikum Essen
-
Frankfurt am Main, 독일, 60488
- 모병
- Krankenhaus NorthWest
-
Hamburg, 독일, 20246
- 모병
- Martini-Klinik am UKE GmbH
-
Heidelberg, 독일, 69120
- 모병
- Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen
-
München, 독일, 81675
- 모병
- Klinikum rechts der Isar der TU Muenchen
-
Münster, 독일, 48149
- 모병
- Universitaetsklinikum Muenster
-
Nuremberg, 독일, 90419
- 모병
- Klinikum Nuernberg Nord
-
Nürtingen, 독일, 72622
- 모병
- Studienpraxis Urologie Nurtingen
-
-
-
-
California
-
La Jolla, California, 미국, 92093
- 모병
- University of California at San Diego
-
Los Angeles, California, 미국, 90048
- 모병
- Cedars Sinai Medical Center
-
Los Angeles, California, 미국, 90095
- 모병
- Ronald Reagan UCLA Medical Center
-
San Francisco, California, 미국, 94121
- 모병
- San Francisco VA Medical Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- University of Colorado Cancer Center
-
Aurora, Colorado, 미국, 80012
- 모병
- Rocky Mountain Cancer Centers
-
Lakewood, Colorado, 미국, 80228
- 모병
- Colorado Clinical Research
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06102
- 모병
- Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20016
- 모병
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
-
-
Florida
-
Bay Pines, Florida, 미국, 33744
- 모병
- Bay Pines VA Healthcare System
-
Fort Myers, Florida, 미국, 33901
- 모병
- Florida Cancer Specialists & Research Institute
-
Tampa, Florida, 미국, 33612
- 모병
- Moffitt Cancer Center
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa Hospital and Clinics
-
Waukee, Iowa, 미국, 50263
- 모병
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, 미국, 70006
- 모병
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 모병
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan Health System
-
Detroit, Michigan, 미국, 48202
- 모병
- Henry Ford Cancer Detroit
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University Of Minnesota Medical Center
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- 완전한
- XCancer Omaha / Urology Cancer Center
-
-
New York
-
Brooklyn, New York, 미국, 11220
- 모병
- NYU Langone Hospitals
-
Mineola, New York, 미국, 11501
- 모병
- NYU Langone Hospital Long Island
-
New York, New York, 미국, 10032
- 모병
- Columbia University Medical Center
-
New York, New York, 미국, 10016
- 모병
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- 모병
- Levine Cancer Institute
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- 모병
- University of Cincinnati
-
Cleveland, Ohio, 미국, 44106
- 모병
- University Hospital of Cleveland
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- VA Portland Health Care System
-
Portland, Oregon, 미국, 97227
- 완전한
- Compass Oncology
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health And Science University
-
Springfield, Oregon, 미국, 97477
- 모병
- Oregon Urology Institute
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, 미국, 19004
- 모병
- MidLantic Urology
-
Lancaster, Pennsylvania, 미국, 17601
- 모병
- Keystone Urology Specialists
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Penn Medicine Abramson Cancer Center
-
Pittsburgh, Pennsylvania, 미국, 15232
- 모병
- UPMC Cancer Centers
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29401
- 모병
- Ralph H Johnson Veterans Hospital
-
Greer, South Carolina, 미국, 29650
- 모병
- Gibbs Cancer Center and Research Institute Pelham
-
Myrtle Beach, South Carolina, 미국, 29572
- 모병
- Carolina Urologic Research Center
-
Spartanburg, South Carolina, 미국, 29303
- 모병
- Gibbs Cancer Center
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37404
- 모병
- Tennessee Oncology - Chattanooga
-
Nashville, Tennessee, 미국, 37203
- 모병
- Tennessee Oncology Nashville
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern Medical Center
-
Dallas, Texas, 미국, 75231
- 완전한
- Urology Clinics of North Texas
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center
-
Houston, Texas, 미국, 77030
- 모병
- Michael E DeBakey VA Medical Center
-
Wichita Falls, Texas, 미국, 76310
- 모병
- Texas Oncology West Texas
-
-
Utah
-
Salt Lake City, Utah, 미국, 84106
- 모병
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- Virginia Cancer Specialists
-
Norfolk, Virginia, 미국, 23502
- 모병
- Virginia Oncology Associates
-
Roanoke, Virginia, 미국, 24014
- 모병
- Blue Ridge Cancer Care
-
-
Washington
-
Seattle, Washington, 미국, 98195
- 모병
- University of Washington
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, 미국, 98108
- 모병
- VA Puget Sound Healthcare System
-
-
-
-
-
Bruges, 벨기에, 8000
- 모병
- AZ Sint-Jan
-
Brussels, 벨기에, 1200
- 모병
- Cliniques Universitaires Saint Luc
-
Ghent, 벨기에, 9000
- 모병
- Ghent University Hospital
-
Ghent, 벨기에, 9000
- 모병
- AZ Maria Middelares
-
Kortrijk, 벨기에, 8500
- 모병
- Az Groeninge
-
La Louvière, 벨기에, 7100
- 모병
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, 벨기에, 4000
- 모병
- CHC MontLegia
-
Ottignies, 벨기에, 1340
- 모병
- Clinique Saint Pierre
-
Wilrijk, 벨기에, 2610
- 모병
- ZAS Augustinus
-
-
-
-
-
Florianópolis, 브라질, 88020 210
- 모병
- Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
Joinville, 브라질, 89201 260
- 모병
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, 브라질, 59062 000
- 모병
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, 브라질, 90035-001
- 모병
- Hospital Moinhos de Vento
-
São Paulo, 브라질, 01509 900
- 모병
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hosp Univ Vall D Hebron
-
Jerez de la Frontera, 스페인, 11407
- 완전한
- Hosp. de Jerez de La Frontera
-
Madrid, 스페인, 28034
- 모병
- Hosp. Univ. Ramon Y Cajal
-
Madrid, 스페인, 28041
- 모병
- Hosp. Univ. 12 de Octubre
-
Málaga, 스페인, 29010
- 모병
- Hosp Virgen de La Victoria
-
-
-
-
-
Birmingham, 영국, B15 2TH
- 모병
- University Hospitals Birmingham NHS Foundation Trust
-
London, 영국, WC1E 6BT
- 모병
- University College London Hospitals
-
Manchester, 영국, M20 4BX
- 모병
- The Christie NHS Foundation Trust Christie Hospital
-
Sutton, 영국, SM2 5PT
- 모병
- Royal Marsden Hospital (Sutton)
-
-
-
-
-
Foggia, 이탈리아, 71122
- 모병
- Ospedali Riuniti Foggia
-
Milan, 이탈리아, 20133
- 모병
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Naples, 이탈리아, 80131
- 모병
- Azienda Ospedaliera Universitaria Federico II
-
Padova, 이탈리아, 35128
- 모병
- IOV IRCCS Padova
-
Palermo, 이탈리아, 90127
- 모병
- Azienda Di Rilievo Nazionale E Di Alta Specializzazione
-
Roma, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, 이탈리아, 20089
- 모병
- Istituto Clinico Humanitas
-
Torino, 이탈리아, 10126
- 모병
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
-
-
-
-
Bunkyō City, 일본, 113 8519
- 모병
- Institute of Science Tokyo Hospital
-
Fukuoka, 일본, 812 8582
- 모병
- Kyushu University Hospital
-
Gifu, 일본, 501-1194
- 모병
- Gifu University Hospital
-
Hidaka, 일본, 350 1298
- 모병
- Saitama Medical University International Medical Center
-
Kanazawa, 일본, 920 8641
- 모병
- Kanazawa University Hospital
-
Kashiwa, 일본, 277 8577
- 모병
- National Cancer Center Hospital East
-
Kobe, 일본, 650 0017
- 모병
- Kobe University Hospital
-
Matsuyama, 일본, 791-0280
- 모병
- National Hospital Organization Shikoku Cancer Center
-
Meguro Ku, 일본, 152 8902
- 모병
- National Hospital Organization Tokyo Medical Center
-
Sakura, 일본, 285-8741
- 모병
- Toho University Sakura Medical Center
-
Sapporo, 일본, 060 8648
- 모병
- Hokkaido University Hospital
-
Yokohama, 일본, 232 0024
- 모병
- Yokohama City University Medical Center
-
Yokohama, 일본, 236 0004
- 모병
- Yokohama City University Hospital
-
Yokosuka, 일본, 238 8558
- 모병
- Yokosuka Kyosai Hospital
-
-
-
-
-
Beijing, 중국, 100034
- 모병
- Peking University First Hospital
-
Changchun, 중국, 130021
- 모병
- The First Bethune Hospital of Jilin University
-
Chengdu, 중국, 610041
- 모병
- West China Hospital of Sichuan University
-
Chengdu, 중국, 500643
- 모병
- The Third People's Hospital of Chengdu
-
Chongqing, 중국, 400030
- 모병
- Chongqing University Cancer Hospital
-
Guangzhou, 중국, 510060
- 모병
- Sun Yat Sen University Cancer Center
-
Nanjing, 중국, 210008
- 모병
- Nanjing Drum Tower Hospital
-
Nanning, 중국, 530021
- 모병
- The First Affiliated Hospital of Guangxi Medical University
-
Nantong, 중국, 226300
- 모병
- Nantong Tumor Hospital
-
Ningbo, 중국, 315010
- 모병
- The First Affiliated Hospital of Ningbo University
-
Shanghai, 중국, 200032
- 모병
- Fudan University Shanghai Cancer Center
-
Tianjin, 중국, 300211
- 모병
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, 중국, 325000
- 모병
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, 중국, 430071
- 모병
- Zhongnan Hospital Wu Han University
-
Xi'an, 중국, 710061
- 모병
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 5G2
- 모병
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 4E6
- 모병
- BC Cancer Vancouver
-
-
Ontario
-
Oshawa, Ontario, 캐나다, L1G2B9
- 모병
- Lakeridge Health
-
Toronto, Ontario, 캐나다, M4N 3M5
- 모병
- Sunnybrook Health Sciences Center
-
Toronto, Ontario, 캐나다, M5G 2C1
- 모병
- Princess Margaret Hospital
-
-
Quebec
-
Québec, Quebec, 캐나다, G1J 1Z4
- 모병
- CHU de Quebec Universite Laval
-
-
-
-
-
Bialystok, 폴란드, 15 276
- 모병
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, 폴란드, 85 048
- 모병
- IN VIVO Sp. z o.o
-
Koszalin, 폴란드, 75-581
- 모병
- Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie
-
Warsaw, 폴란드, 02 781
- 모병
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, 폴란드, 04 073
- 모병
- Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O
-
-
-
-
-
Rio Piedras, 푸에르토 리코, 00935
- 모병
- Pan American Center for Oncology Trials LLC
-
San Juan, 푸에르토 리코, 00917
- 모병
- Puerto Rico Medical Research Center
-
-
-
-
-
Bordeaux, 프랑스, 33000
- 모병
- Institut Bergonie
-
Brest, 프랑스, 29200
- 모병
- CHRU Brest - Hopital Morvan
-
Dijon, 프랑스, 21000
- 모병
- Centre Georges Francois Leclerc
-
Lille, 프랑스, 59000
- 모병
- Centre Oscar Lambret
-
Lyon, 프랑스, 69008
- 모병
- Centre Leon Berard
-
Paris, 프랑스, 75014
- 모병
- Hopital Saint Joseph
-
Pierre-Bénite, 프랑스, 69495
- 모병
- CHU Lyon Sud
-
Saint-Herblain, 프랑스, 44805
- 모병
- I.C.O. Rene Gauducheau
-
Strasbourg, 프랑스, 672098
- 모병
- Hopitaux universitaires de Strasbourg
-
Vandœuvre-lès-Nancy, 프랑스, 54519
- 모병
- Institut de Cancerologie de Lorraine
-
Villejuif, 프랑스, 94800
- 모병
- Gustave Roussy
-
-
-
-
-
Heidelberg, 호주, 3084
- 모병
- Warringal Private Hospital
-
Kurralta Park, 호주, 5037
- 모병
- ICON Cancer Care
-
Melbourne, 호주, 3000
- 모병
- Peter MacCallum Cancer Centre
-
Murdoch, 호주, 6150
- 모병
- Fiona Stanley Hospital
-
Woolloongabba, 호주, 4102
- 모병
- Princess Alexandra Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- Histologically confirmed adenocarcinoma of the prostate
- Metastatic castration-resistant prostate cancer (mCRPC): Disease that is metastatic either to bone, any lymph node, or both without clear evidence of other metastatic sites at the time of screening by conventional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (chest, abdomen, and pelvis) and 99m^Tc bone scan. Visceral disease is not allowed
- PSA greater than or equal to (≥) 2 nanogram per milliliter (ng/mL) at screening
- In the opinion of the investigator, the next best treatment option is a clinical trial
- Participants are required to have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access. Prior therapies could have been given in any disease setting (not limited to mCRPC). In particular, prior treatment specifications include receipt of the following:
Androgen-receptor pathway inhibitor (ARPI): Must have progressed on at least 1 ARPI and unlikely to benefit from retreatment with another ARPI
Taxanes: Required to have received at least 2 previous taxane-based regimens. If a participant has received only 1 taxane regimen, the participant is eligible if:
- Cabazitaxel is not available
- The participant's physician deems the participant unsuitable to receive a second taxane regimen due to toxicity risk or prior intolerance Note: a taxane-based regimen consists of at least 2 cycles of a taxane (either as a single agent or in combination with other therapies) administered within the same 2-month period
Radioligand therapy: Required to have been previously treated with at least 1 dose of Prostate-specific membrane antigen (PSMA)-targeted lutetium radioligand therapy (eg, lutetium Lu-177 vipivotide tetraxetan), unless one of the following applies:
- PSMA-targeted lutetium radioligand therapy is unavailable, not accessible, or not clinically indicated.
- The participant's physician deems the participant unsuitable to receive PSMA-targeted lutetium radioligand therapy.
Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi): Required to have been previously treated with PARPi, if the participant has a known germline or somatic BRCA mutation and treatment is available
- Prior orchiectomy or medical castration (receiving ongoing ADT with a GnRH analog [agonist or antagonist]) prior to the first dose of study treatment and must continue this therapy throughout the treatment phase
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Participants are eligible if they have the following values:
A) eGFR ≥ 40 milliliters per minute (mL/min) B) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) less than or equal to (≤) 3 times the Upper Limit of Normal (ULN) C) Total bilirubin <1.5 times ULN D) Absolute neutrophil count (ANC) ≥ 1.0x10^9/per liter (L) E) Hemoglobin ≥ 8.0 grams per deciliter (g/dL) F) Platelet count ≥ 75x10^9/L
Exclusion Criteria
- Venous thromboembolic events within 1 month prior to the first dose of study treatment; uncomplicated (Grade ≤ 2) deep vein thrombosis is not exclusionary
- Active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications (eg, chronic corticosteroid, methotrexate, or tacrolimus)
- Participants with Grade 1 or higher fever (≥38ºC) or active infection requiring systemic treatment within 7 days prior to randomization are ineligible. Participants must be afebrile (<38ºC) at the time of study treatment dosing unless approved by medical monitor
- Clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use (>2 liters per minute (L/min) by nasal cannula) to maintain adequate oxygenation
- Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Any of the following within 6 months prior to first dose of study treatment:
A) Myocardial infarction B) Severe or unstable angina C) Clinically significant ventricular arrhythmias D) Congestive heart failure (New York Heart Association class II to IV) E) Transient ischemic attack F) Cerebrovascular accident
- Prior treatment with any CD3-directed therapy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1: Pasritamig+Best Supportive Care (BSC)
Participants in Part 1 will receive 2 step-up doses of pasritamig intravenously (IV) followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
다른 이름들:
BSC will be administered at the discretion of the treating physician. |
|
위약 비교기: Part 1: Placebo+BSC
Participants in Part 1 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
|
실험적: Part 2: Pasritamig+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
다른 이름들:
BSC will be administered at the discretion of the treating physician. |
|
실험적: Part 2: Pasritamig+JNJ-87189401+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. JNJ-87189401 will be administered with the first target dose of pasritamig. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
다른 이름들:
BSC will be administered at the discretion of the treating physician. JNJ-87189401 will be administered. |
|
위약 비교기: Part 2: Placebo +BSC
Participants in Part 2 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: Up to 2 years and 8 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to 2 years and 8 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Radiographic Progression-free Survival (rPFS)
기간: Up to 2 years and 8 months
|
rPFS assessed by investigator defined as the time from the date of randomization until the date of radiographic disease progression (based on response evaluation criteria in solid tumors [RECIST] version (v) 1.1 and prostate cancer working group 3 [PCWG3] criteria) or death, whichever comes first. |
Up to 2 years and 8 months
|
|
Time to Symptomatic Progression
기간: Up to 2 years and 8 months
|
Time to symptomatic progression is defined as time from the date of randomization to the date of any of the following (whichever occurs first): (a) the use of external beam radiation therapy to relieve cancer-related symptoms; (b) the need for tumor-related orthopedic surgical intervention; (c) other cancer-related procedures; (d) cancer-related morbid events; (e) initiation of a new systemic anti-cancer therapy because of cancer symptoms. |
Up to 2 years and 8 months
|
|
Time to Skeletal-Related Event
기간: Up to 2 years and 8 months
|
Time to skeletal-related event is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): (a) the use of external beam radiation for skeletal or pelvic symptoms; b) the need for tumor-related orthopedic surgical intervention; (c) the occurrence of new bone fractures (cancer-related); (d) the occurrence of tumor-related spinal cord compression. |
Up to 2 years and 8 months
|
|
Progression-Free Survival (PFS)
기간: Up to 2 years and 8 months
|
PFS is defined as the date of randomization to the date of first evidence of radiographic progression, clinical progression, or death from any cause, whichever occurs first. |
Up to 2 years and 8 months
|
|
Time to Prostate Specific Antigen (PSA) Progression
기간: Up to 2 years and 8 months
|
Time to PSA progression, defined as the time from randomization to the first date of documented PSA progression per PCWG3 criteria. PSA progression is defined as: after a decline from baseline, PSA increases >= 25 percentage (%) and >= 2 nanograms per milliliter (ng/mL) above the nadir, confirmed by a second value >= 3 weeks later (that is, a confirmed rising trend), or If there is no decline from baseline, PSA increases >= 25 % and >= 2 ng/mL from baseline after 12 weeks. |
Up to 2 years and 8 months
|
|
Time to Pain Progression (TTPP) as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) Item 3 Worst Pain in 24 Hours
기간: Up to 2 years and 8 months
|
TTPP is defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression is defined as an increase of at least 2 points from baseline in the BPI-SF worst pain intensity (item 3) observed at 2 consecutive evaluations >= 3 weeks apart. BPI-SF is an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score range from 0 to 10 with 0 representing "no pain" and 10 representing" pain as bad as you can imagine". |
Up to 2 years and 8 months
|
|
Time to Deterioration in Fatigue as Assessed by the European Organisation For Research And Treatment of Cancer Quality of Life Questionnaire-Core-30 (EORTC QLQ-C30) Fatigue Scale Score
기간: Up to 2 years and 8 months
|
Time to deterioration is defined as the time from randomization to the date of the first observation of deterioration in Fatigue. Deterioration in Fatigue is defined as an increase of 10 points on the EORTC QLQ-C30 FA scale observed at 2 consecutive evaluations >= 3 weeks apart. The EORTC QLQ-C30 is a widely used tool for assessing the quality of life of cancer patients in clinical trials. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". Each subscale of the EORTC QLQ-C30 is scored on a range from 0 to 100. Higher scores indicate worse symptoms or problems. |
Up to 2 years and 8 months
|
|
Number of Participants with Adverse Events (AEs)
기간: Up to 2 years and 8 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years and 8 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
기간: Up to 2 years and 8 months
|
Participants with abnormalities in clinical laboratory parameters (hematology, clinical chemistry etc.) will be assessed. |
Up to 2 years and 8 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 78278343PCR3001
- 2025-520927-26-00 (레지스트리 식별자: EUCT number)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .